BioXcel Therapeutics, Inc. (BTAIQ)
0.052
+0.01
(+15.56%)
USD |
OTCM |
Oct 02, 16:00
BioXcel Therapeutics Gross Profit Margin (Quarterly) : 78.02% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 78.02% |
| March 31, 2026 | -65.53% |
| December 31, 2025 | 58.59% |
| September 30, 2025 | 12.24% |
| June 30, 2025 | -51.67% |
| March 31, 2025 | 46.43% |
| December 31, 2024 | -148.4% |
| September 30, 2024 | -482.7% |
| Date | Value |
|---|---|
| June 30, 2024 | 87.41% |
| March 31, 2024 | 72.85% |
| December 31, 2023 | -110.6% |
| September 30, 2023 | -73.31% |
| June 30, 2023 | 60.83% |
| March 31, 2023 | 56.80% |
| December 31, 2022 | 62.18% |
| September 30, 2022 | 29.93% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Agenus, Inc. | 98.50% |
| Amgen, Inc. | 72.08% |
| BioCryst Pharmaceuticals, Inc. | 98.01% |
| Imunon, Inc. | -- |
| Curis, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -195.8% |
| Return on Invested Capital | -1.21K% |
| Profit Margin (Quarterly) | -8.08K% |
| Operating Margin (Quarterly) | -5.54K% |
| Return on Net Operating Assets | -1.34K% |